Format

Send to

Choose Destination
PLoS One. 2015 Apr 23;10(4):e0119265. doi: 10.1371/journal.pone.0119265. eCollection 2015.

Multimarker proteomic profiling for the prediction of cardiovascular mortality in patients with chronic heart failure.

Author information

1
INSERM UMR1167, Lille, France; Institut Pasteur de Lille, Lille, France; Université Lille Nord de France, Lille, France; Centre Hospitalier Régional et Universitaire de Lille, Lille, France; Faculté de Médecine de Lille, Lille, France.
2
INSERM UMR1167, Lille, France; Institut Pasteur de Lille, Lille, France; Centre Hospitalier Régional et Universitaire de Lille, Lille, France.
3
INSERM UMR1167, Lille, France; Institut Pasteur de Lille, Lille, France; Université Lille Nord de France, Lille, France.
4
INSERM UMR1167, Lille, France; Institut Pasteur de Lille, Lille, France; Université Lille Nord de France, Lille, France; Centre Hospitalier Régional et Universitaire de Lille, Lille, France.

Abstract

Risk stratification of patients with systolic chronic heart failure (HF) is critical to better identify those who may benefit from invasive therapeutic strategies such as cardiac transplantation. Proteomics has been used to provide prognostic information in various diseases. Our aim was to investigate the potential value of plasma proteomic profiling for risk stratification in HF. A proteomic profiling using surface enhanced laser desorption ionization - time of flight - mass spectrometry was performed in a case/control discovery population of 198 patients with systolic HF (left ventricular ejection fraction <45%): 99 patients who died from cardiovascular cause within 3 years and 99 patients alive at 3 years. Proteomic scores predicting cardiovascular death were developed using 3 regression methods: support vector machine, sparse partial least square discriminant analysis, and lasso logistic regression. Forty two ion m/z peaks were differentially intense between cases and controls in the discovery population and were used to develop proteomic scores. In the validation population, score levels were higher in patients who subsequently died within 3 years. Similar areas under the curves (0.66 - 0.68) were observed for the 3 methods. After adjustment on confounders, proteomic scores remained significantly associated with cardiovascular mortality. Use of the proteomic scores allowed a significant improvement in discrimination of HF patients as determined by integrated discrimination improvement and net reclassification improvement indexes. In conclusion, proteomic analysis of plasma proteins may help to improve risk prediction in HF patients.

PMID:
25905469
PMCID:
PMC4408082
DOI:
10.1371/journal.pone.0119265
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center